chronic diarrhea
Conditions
Interventions
Gold Standard:The disease to be diagnosed in this study is the organic/functional cause of chronic diarrhea. Therefore, the diagnosis of organic diarrhea is determined by symptom + history + colonosco
Index test:1) fecal calcaretin concentration
2) Serological indexes of mucosal injury: 1. Diamine oxidase
2. Lactic acid
2. 3. Bacterial endotoxin and 4. Serum Zonulin protein.
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Subjects with chronic diarrhea: 1) Male and female, =18 years old; 2) Duration of diarrhea =3 months, accompanied by stool frequency =2 times/day, or the stool character is mushy/watery (Bristol stools type 6, 7); 3) To undergo colonoscopy/pathological biopsy; 4) Agree to participate in this clinical study and sign informed consent. Healthy control: 1) Male and female, =18 years old; Gender, age, and BMI were matched with the case group; 2) No symptoms of diarrhea, good health condition, no current digestive disease, and no history of severe digestive disease or other serious diseases; 3) Agree to participate in the clinical study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1) Ascites, abdominal mass, or history of abdominal/pelvic surgery, such as biliopancreatic surgery (patients who have received appendectomy or cesarean section without intestinal complications such as intestinal obstruction; Patients who had received endoscopic treatment for intestinal polyps were not excluded); 2) A history of the following diseases: diffuse small bowel disease, diabetic phytoneuropathy, hyperthyroid-related diarrhea, carcinoid syndrome, pheochromocytoma, Addison's disease, serious systemic diseases (immune system diseases are not excluded); 3) Diarrhea is associated with long-term or recent use of laxatives; 4) Known or suspected gastrointestinal obstruction, stenosis, fistula or active bleeding, and other conditions that cannot be colonoscopically detected; 5) Pregnant or lactating women; 6) Patients with mental illness (unable to cooperate with research or unable to sign informed consent); 7) Subjects who have participated in or are participating in other clinical trials within three months; 8) The researcher considers that there are any other influencing factors that may not be appropriate for the subject to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The results of the colonoscopy;Fecal calprotectin concentration;Efficacy of fecal calprotectin testing in the diagnosis of chronic organic diarrhea; | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptoms associated with diarrhea in patients;Intestinal biopsy results;Intestinal permeability;The sensitivity and specificity of fecal calprotectin in the detection of different types of organic chronic diarrhea (IBD active or inactive stage, tumor, intestinal tuberculosis, and microscopic mucosal inflammation);Sensitivity and specificity of fecal calprotectin detection in different types of functional chronic diarrhea (IBS-D, FDr, etc.);To explore the sensitivity and specificity of calprotectin combined with colonoscopy in the detection of microscopic mucosal inflammation;To explore the sensitivity and specificity of calprotectin in the detection of chronic diarrhea;Preliminary exploration of the sensitivity and specificity of calprotectin combined with mucosal injury serologic indicators or mucosal injury serological indicators alone in the detection of organic diarrhea; | — |
Countries
China
Contacts
Public ContactXiaohua Hou
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed